David Gruben
Impact in
- Rheumatology top 0.05%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 71
- Rheumatoid Arthritis Research and Therapies 65
- Systemic Lupus Erythematosus Research 8
- Spondyloarthritis Studies and Treatments 6
- Hematology 14
- Autoimmune and Inflammatory Disorders Research 14
- Co-authors
- Samuel H. Zwillich (36 shared papers)Gene V. Wallenstein (30 shared papers)Sriram Krishnaswami (16 shared papers)Roy Fleischmann (22 shared papers)John Bradley (22 shared papers)Joel M. Kremer (18 shared papers)Bethanie Wilkinson (19 shared papers)Tamás Koncz (15 shared papers)
- Journals
- Annals of the Rheumatic Diseases (26 papers)RMD Open (5 papers)Rheumatology and Therapy (5 papers)Dermatology and Therapy (4 papers)Arthritis Research & Therapy (4 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
David Gruben
97 papers receiving 6.3k citations
David Gruben's Hit Papers
Peers
Comparison fields: 5 of 117
- Rheumatology 4.2k
- Hematology 1.2k
- Genetics 755
- Immunology 1.1k
- Oncology 1.2k
Countries citing papers authored by David Gruben
This map shows the geographic impact of David Gruben's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Gruben with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Gruben more than expected).
Fields of papers citing papers by David Gruben
This network shows the impact of papers produced by David Gruben. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Gruben. The network helps show where David Gruben may publish in the future.
Co-authors
The 25 scholars most cited alongside David Gruben, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 103 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis Hit paper breakdown → | 2012 | 823 |
| 2 | Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis Hit paper breakdown → | 2012 | 769 |
| 3 | Tofacitinib versus Methotrexate in Rheumatoid Arthritis Hit paper breakdown → | 2014 | 620 |
| 4 | Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial Hit paper breakdown → | 2013 | 568 |
| 5 | Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study Hit paper breakdown → | 2013 | 462 |
| 6 | The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo Hit paper breakdown → | 2009 | 453 |
| 7 | Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis Hit paper breakdown → | 2013 | 373 |
| 8 | Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs Hit paper breakdown → | 2011 | 323 |
| 9 | 2011 | 288 | |
| 10 | Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies Hit paper breakdown → | 2014 | 265 |
| 11 | 2013 | 191 | |
| 12 | 2009 | 117 | |
| 13 | 2019 | 71 | |
| 14 | 2016 | 62 | |
| 15 | 2016 | 58 | |
| 16 | 2015 | 52 | |
| 17 | 2014 | 51 | |
| 18 | 2016 | 51 | |
| 19 | 2020 | 48 | |
| 20 | 2016 | 43 |
About David Gruben
David Gruben is a scholar working on Rheumatology, Hematology, Immunology, Genetics and Genetics, having authored 103 papers that have together received 6.5k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (65 papers), Autoimmune and Inflammatory Disorders Research (14 papers), Chronic Lymphocytic Leukemia Research (11 papers), Biosimilars and Bioanalytical Methods (9 papers), Inflammatory Bowel Disease (9 papers), Systemic Lupus Erythematosus Research (8 papers), Dermatology and Skin Diseases (6 papers) and Spondyloarthritis Studies and Treatments (6 papers). The work is most often cited by research in Rheumatology (4.2k citations), Hematology (1.2k citations), Genetics (755 citations), Immunology (1.1k citations) and Oncology (1.2k citations). David Gruben has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Samuel H. Zwillich, Gene V. Wallenstein, Sriram Krishnaswami, Roy Fleischmann, John Bradley, Joel M. Kremer, Bethanie Wilkinson, Tamás Koncz, Carol A. Connell and Eun Bong Lee. Their work appears in journals such as Annals of the Rheumatic Diseases, RMD Open, Rheumatology and Therapy, Dermatology and Therapy and Arthritis Research & Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.